{"id":"bcx4208","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Gout"},{"rate":null,"effect":"Lymphopenia"}]},"_chembl":{"chemblId":"CHEMBL2107835","moleculeType":"Small molecule","molecularWeight":"682.69"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"By inhibiting PNP, BCX4208 causes accumulation of deoxyadenosine, which is preferentially toxic to T cells with high deoxyadenosine kinase activity, particularly autoreactive T cells. This selective depletion of pathogenic T cells while sparing regulatory T cells creates an immunomodulatory effect intended to treat autoimmune and inflammatory conditions. The mechanism allows for targeted immune suppression without broad immunosuppression.","oneSentence":"BCX4208 is a PNP (purine nucleoside phosphorylase) inhibitor that increases deoxyadenosine levels to selectively expand T-regulatory cells and suppress autoreactive immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:22:30.633Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Autoimmune conditions (Phase 2 development)"},{"name":"Inflammatory disorders"}]},"trialDetails":[{"nctId":"NCT01407874","phase":"PHASE2","title":"A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2011-09","conditions":"Gout, Hyperuricemia, Arthritis","enrollment":20},{"nctId":"NCT01265264","phase":"PHASE2","title":"Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2010-12","conditions":"Gout, Hyperuricemia, Arthritis","enrollment":279},{"nctId":"NCT00985127","phase":"PHASE2","title":"Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2009-09","conditions":"Gout","enrollment":99},{"nctId":"NCT01129648","phase":"PHASE2","title":"Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2010-05","conditions":"Gout","enrollment":87}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BCX4208","genericName":"BCX4208","companyName":"BioCryst Pharmaceuticals","companyId":"biocryst-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BCX4208 is a PNP (purine nucleoside phosphorylase) inhibitor that increases deoxyadenosine levels to selectively expand T-regulatory cells and suppress autoreactive immune responses. Used for Autoimmune conditions (Phase 2 development), Inflammatory disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}